Market closed

Lineage Cell Therapeutics/LCTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Lineage Cell Therapeutics

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Ticker

LCTX

Trading on

AMEX

Industry

Biotechnology

Employees

72

LCTX Metrics

BasicAdvanced
$172M
Market cap
-
P/E ratio
-$0.13
EPS
1.30
Beta
-
Dividend rate
$172M
1.3
$1.61
$0.77
360K
2.644
2.536
2.745
4.413
-12.86%
-35.04%
26.541
2.52
15.5
-7.351
-41.22%
3.13%
50.11%
19.89%

What the Analysts think about LCTX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Lineage Cell Therapeutics stock.

LCTX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

LCTX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy LCTX

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Lineage Cell Therapeutics stock?

Lineage Cell Therapeutics (LCTX) has a market cap of $172M as of October 06, 2024.

What is the P/E ratio for Lineage Cell Therapeutics stock?

The price to earnings (P/E) ratio for Lineage Cell Therapeutics (LCTX) stock is 0 as of October 06, 2024.

Does Lineage Cell Therapeutics stock pay dividends?

No, Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders as of October 06, 2024.

When is the next Lineage Cell Therapeutics dividend payment date?

Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Lineage Cell Therapeutics?

Lineage Cell Therapeutics (LCTX) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.